Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform.

We report the engineering of a novel lipid-polymer hybrid nanoparticle (NP) as a robust drug delivery platform, with high drug encapsulation yield, tunable and sustained drug release profile, excellent serum stability, and potential for differential targeting of cells or tissues. The NP comprises three distinct functional components: (i) a hydrophobic polymeric core where poorly water-soluble drugs can be encapsulated; (ii) a hydrophilic polymeric shell with antibiofouling properties to enhance NP stability and systemic circulation half-life; and (iii) a lipid monolayer at the interface of the core and the shell that acts as a molecular fence to promote drug retention inside the polymeric core, thereby enhancing drug encapsulation efficiency, increasing drug loading yield, and controlling drug release. The NP is prepared by self-assembly through a single-step nanoprecipitation method in a reproducible and predictable manner, making it potentially suitable for scale-up.

[1]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[2]  K. Skubitz Phase II Trial Of Pegylated-liposomal Doxorubicin (Doxil™) In Sarcoma* , 2003, Cancer investigation.

[3]  Laurent David,et al.  Steric stabilization of lipid/polymer particle assemblies by poly(ethylene glycol)-lipids. , 2007, Biomacromolecules.

[4]  Omid C Farokhzad,et al.  Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates , 2007, ChemMedChem.

[5]  Tae-You Kim,et al.  Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies , 2004, Clinical Cancer Research.

[6]  R. Langer,et al.  Nanomedicine: developing smarter therapeutic and diagnostic modalities. , 2006, Advanced drug delivery reviews.

[7]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  L. Zhang,et al.  Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.

[9]  V. Torchilin Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[10]  M. Ferrari Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[11]  J Szebeni,et al.  Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.

[12]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[13]  Ignacio De Miguel,et al.  Proofs of the Structure of Lipid Coated Nanoparticles (SMBV™) Used as Drug Carriers , 2000, Pharmaceutical Research.

[14]  Robert Langer,et al.  Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers , 2008, Proceedings of the National Academy of Sciences.

[15]  X. Wu,et al.  Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[16]  Volker Wagner,et al.  The emerging nanomedicine landscape , 2006, Nature Biotechnology.

[17]  Jianjun Cheng,et al.  Anticancer Polymeric Nanomedicines , 2007 .

[18]  Warren C W Chan,et al.  Nanoparticle-mediated cellular response is size-dependent. , 2008, Nature nanotechnology.

[19]  V. Torchilin,et al.  Micellar Nanocarriers: Pharmaceutical Perspectives , 2006, Pharmaceutical Research.

[20]  D. S. Coffey,et al.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.